J
Jacek Pinski
Researcher at University of Southern California
Publications - 155
Citations - 5102
Jacek Pinski is an academic researcher from University of Southern California. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 41, co-authored 153 publications receiving 4786 citations. Previous affiliations of Jacek Pinski include United States Department of Veterans Affairs & Tulane University.
Papers
More filters
Journal ArticleDOI
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results
Siamak Daneshmand,Marcus L. Quek,John P. Stein,Gary Lieskovsky,Jie Cai,Jacek Pinski,Eila C. Skinner,Donald G. Skinner +7 more
TL;DR: Local tumor bulk and the number/percent of involved lymph nodes significantly affect disease progression and the survival rate and radical prostatectomy may offer long-term survival in patients who have limited tumor Bulk and nodal involvement.
Journal ArticleDOI
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival
Siamak Daneshmand,Marcus L. Quek,Edward Lin,Charlotte Lee,Richard J. Cote,Debra Hawes,Jie Cai,Susan Groshen,Gary Lieskovsky,Donald G. Skinner,Amy S. Lee,Jacek Pinski +11 more
TL;DR: It is confirmed that GRP78 protein expression is significantly higher in prostate cancer than in benign prostatic tissue and the intensity of expression is significant associated with survival and clinical recurrence.
Journal ArticleDOI
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff,Bryan Goldman,Jacek Pinski,Philip C. Mack,Primo N. Lara,Peter J. Van Veldhuizen,David I. Quinn,Nicholas J. Vogelzang,Ian M. Thompson,Maha Hussain +9 more
TL;DR: A multicenter phase II study of CNTO328 (siltuximab) as second-line therapy for men with castration-resistant prostate cancer resulted in a PSA response rate of 3.8% and a RECIST stable disease rate of 23%.
Journal ArticleDOI
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Himisha Beltran,Himisha Beltran,Clara Oromendia,Daniel C. Danila,Daniel C. Danila,Bruce Montgomery,Christopher J. Hoimes,Russell Z. Szmulewitz,Ulka N. Vaishampayan,Andrew J. Armstrong,Mark N. Stein,Jacek Pinski,Juan Miguel Mosquera,Juan Miguel Mosquera,Verena Sailer,Rohan Bareja,Alessandro Romanel,Naveen Gumpeni,Andrea Sboner,Andrea Sboner,Etienne Dardenne,Loredana Puca,Loredana Puca,Davide Prandi,Mark A. Rubin,Mark A. Rubin,Howard I. Scher,Howard I. Scher,David S. Rickman,David S. Rickman,Francesca Demichelis,Francesca Demichelis,David M. Nanus,David M. Nanus,Karla V. Ballman,Scott T. Tagawa,Scott T. Tagawa +36 more
TL;DR: Although the study did not meet its primary endpoint, a subset of patients with advanced prostate cancer and molecular features supporting Aurora-A and N-myc activation achieved significant clinical benefit from single-agent alisertib.
Journal ArticleDOI
EphB4 Expression and Biological Significance in Prostate Cancer
Guangbin Xia,S. Ram Kumar,Rizwan Masood,Sutao Zhu,Ramchandra Reddy,Valery Krasnoperov,David I. Quinn,Susan M. Henshall,Robert L. Sutherland,Jacek Pinski,Siamak Daneshmand,Maurizio Buscarini,John P. Stein,Chen Zhong,Daniel Broek,Pradip Roy-Burman,Parkash S. Gill +16 more
TL;DR: A role for EphB4 in prostate cancer is shown and a rationale to study E phB4 for diagnostic, prognostic, and therapeutic applications is provided.